Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial

Andrew H Wei; Gail J Roboz; Herve Dombret; Hartmut Dohner; Andre C Schuh; Pau Montesinos; Dominik Selleslag; Sergey N Bondarenko; Thomas Prebet; Yinzhi Lai; Barry Skikne; C L Beach; Farhad Ravandi

doi:10.3324/haematol.2022.282296

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial

Haematologica. 2023 Oct 1;108(10):2820-2825. doi: 10.3324/haematol.2022.282296.

Authors

Andrew H Wei¹, Gail J Roboz², Herve Dombret³, Hartmut Dohner⁴, Andre C Schuh⁵, Pau Montesinos⁶, Dominik Selleslag⁷, Sergey N Bondarenko⁸, Thomas Prebet⁹, Yinzhi Lai⁹, Barry Skikne¹⁰, C L Beach⁹, Farhad Ravandi¹¹

Affiliations

¹ Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne. andrew.wei@petermac.org.
² Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, New York, NY.
³ Hematology, Hopital Saint-Louis, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Universite Paris Cite, Paris.
⁴ Department of Internal Medicine III, Ulm University Hospital, Ulm.
⁵ Princess Margaret Cancer Centre, Toronto, ON.
⁶ Hospital Universitario y Politecnico La Fe, Valencia.
⁷ AZ Sint-Jan Brugge-Oostende AV, Bruges.
⁸ RM Gorbacheva Research Institute, Pavlov University, St. Petersburg.
⁹ Bristol Myers Squibb, Summit, NJ.
¹⁰ Bristol Myers Squibb, Summit, NJ, USA; University of Kansas Cancer Center, Kansas City, KS.
¹¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Clinical Trial, Phase III
Letter

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Azacitidine* / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / mortality
Remission Induction

Substances

Antimetabolites, Antineoplastic
Azacitidine

Associated data

ClinicalTrials.gov/NCT01757535

Grants and funding

Funding: Writing and editorial support was provided by Korin Albert, PhD, of Excerpta Medica, funded by Bristol Myers Squibb. The study was sponsored by Bristol Myers Squibb.